Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to -$27.8 million.

  • Entrada Therapeutics' Cash from Investing Activities rose 159.22% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year increase of 327.07%. This contributed to the annual value of -$27.8 million for FY2024, which is 79.91% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Cash from Investing Activities of -$27.8 million as of FY2024, which was up 79.91% from -$138.4 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Cash from Investing Activities ranged from a high of -$2.3 million in FY2020 and a low of -$148.7 million during FY2022.
  • For the 3-year period, Entrada Therapeutics' Cash from Investing Activities averaged around -$104.9 million, with its median value being -$138.4 million (2023).
  • Per our database at Business Quant, Entrada Therapeutics' Cash from Investing Activities slumped by 3,145.63% in 2022 and then surged by 79.91% in 2024.
  • Yearly analysis of 5 years shows Entrada Therapeutics' Cash from Investing Activities stood at -$2.3 million in 2020, then tumbled by 97.58% to -$4.6 million in 2021, then slumped by 3,145.63% to -$148.7 million in 2022, then increased by 6.90% to -$138.4 million in 2023, then spiked by 79.91% to -$27.8 million in 2024.